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ABSTRACT
Currently, the control of schizophrenia symptoms is primarily through
pharmacological intervention. However, antipsychotics can cause several sideeffects, such as extrapyramidal symptoms (EPS) and body weight gain/obesity,
which severely affect patient compliance to continue with medication. In addition,
due to the effects of antipsychotics on neurotransmission, it is unclear whether
central pathological changes observed in post-mortem tissue in schizophrenia are
the real pathology of the disease or are a result of the effects of antipsychotic
drugs. The aim of this study was to investigate the molecular mechanisms of the
pharmacological efficacy and side-effects of antipsychotic drugs. To achieve this
aim, this study examined the expression of dopamine D2, histamine H1, serotonin
5HT1A and muscarinic M1 receptors in the rat brain following short-term (1 week)
and long-term (12 weeks) treatment with aripiprazole, olanzapine and haloperidol.

Aripiprazole and haloperidol both have a high affinity for dopamine D2 receptors,
however aripiprazole has a lower risk of EPS than haloperidol. The aim of
Chapter 2 was to understand the mechanism underlying why aripiprazole, unlike
haloperidol, has a therapeutic effect but does not induce significant EPS. Results
showed that aripiprazole selectively increased D2 receptor mRNA expression and
decreased tyrosine hydroxylase mRNA expression (TH; a rate-limiting enzyme
for the synthesis of dopamine) in the ventral tegmental area (VTA), but not the
substantia nigra (SN). Aripiprazole also decreased dopamine transporter (DAT)
binding density in the nucleus accumbens (NAc) and VTA. Consistent with

x

previous findings, haloperidol significantly increased D2 receptor binding density,
but decreased DAT binding density in the NAc, CPu and VTA. Olanzapine had
less widespread effects on D2 receptor expression and DAT binding density.
These results suggest that aripiprazole may control schizophrenia symptoms
through a novel mechanism: that is, by selectively reducing dopamine synthesis in
the VTA but not SN. This may contribute to the long-term efficacy of aripiprazole
in controlling schizophrenia symptoms with reduced EPS.

It has been previously reported that aripiprazole and olanzapine increased
dopamine release in the prefrontal cortex via the serotonin 5-HT1A receptor, which
may partially explain why these drugs can improve the negative symptoms and
cognitive functional deficits associated with schizophrenia. It is interesting that
aripiprazole has a high affinity for 5-HT1A receptors, but olanzapine has not.
Therefore, the aim of Chapter 3 was to examine whether these antipsychotics
affect 5-HT1A receptor expression. The results showed that aripiprazole increased
5-HT1A binding density in the CA1 region of the hippocampus and medial
posterodorsal nuclei of the posterior amygdala (MeP), while olanzapine downregulated the binding density of 5-HT1A receptors in the cingulate cortex.
However, these changes were not apparent after 12 weeks of drug treatment. This
study suggests that aripiprazole and olanzapine have different effects on the
binding density of 5-HT1A receptors. The results indicate that aripiprazole and
olanzapine have differential effects on 5-HT1A protein expression, which may
contribute to their distinct profiles in improving negative symptoms and cognitive
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deficits in schizophrenia. However, they may induce adaptation and
desensitisation in serotonin 5-HT1A receptor expression after long-term treatment.

Schizophrenia patients exhibit a decrease, or no change, in muscarinc M1 receptor
expression in certain brain regions. Olanzapine has a high affinity for the M1
receptor, while aripiprazole and haloperidol have low affinities. The aim of
Chapter 4 was to investigate how these antipsychotics affect M1 receptor mRNA
expression in regions of the brain that are implicated in the pathology of
schizophrenia. This study showed that the three antipsychotics increased M1
receptor mRNA expression in the hippocampus. In addition, increases in M1
receptor mRNA expression were also observed in the SN following treatment
with haloperidol and olanzapine, and in the NAc following treatment with
aripiprazole. These results suggest that alterations of M1 receptor mRNA
expression in schizophrenia are unlikely to be a consequence of drug treatment,
and implicate the muscarinic M1 receptor as a contributor to the therapeutic
effects of schizophrenia treatments.

The aim of Chapter 5 was to investigate whether the body weight gain/obesity
side-effect of olanzapine was produced by regulating histamine H1 receptor
expression. To the best of this author’s knowledge, this study is the first to
compare H1 receptor expression in the rat brain following short and long-term
administration of olanzapine, aripiprazole and haloperidol. Results showed that
olanzapine significantly down-regulated H1 receptor mRNA expression and
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binding density in the ventromedial hypothalamic nucleus (VMH), and H1
receptor mRNA expression in the arcuate hypothalamic nucleus (Arc). Consistent
with their low risk of weight gain/obesity side-effect, aripiprazole and haloperidol
had no effect on H1 receptor expression in the VMH or Arc. Histamine H1
receptor mRNA expression in the VMH and Arc were negatively correlated to
body weight gain and energy efficiency, while H1 receptor mRNA expression in
the Arc showed negative correlations to food intake and total fat mass. In
addition, there was a negative relationship between H1 receptor binding densities
in the VMH and total fat mass and body weight gain. This study suggests that an
olanzapine-induced down-regulation of histamine H1 receptor expression in
regions of hypothalamus involved in the regulation of food intake (the Arc and
VMH) may be a key factor contributing to olanzapine-induced body weight
gain/obesity.

In conclusion, this study revealed that the effects of antipsychotics on specific
neurotransmitter receptors contribute to the mechanisms of their pharmacological
efficacy and side-effects. The binding profiles of antipsychotics for specific
receptors cannot completely predict the level of their therapeutic efficacies and
side-effects. Furthermore, the changes in expression of some receptors (such as 5HT1A) by antipsychotic treatment may produce the adaptation and desensitisation
after long-term use. These results have also provided significant information
which may assist with the development of new antipsychotic drugs.
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